Dermatan sulfate as a potential antithrombotic drug

Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study.

Thrombosis and haemostasis·2002

A placebo-controlled, double-blind study of mesoglycan in the treatment of chronic venous ulcers.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2001

Clinical outcome and its predictors in 1560 patients with critical leg ischaemia. Chronic Critical Leg Ischaemia Group.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·1999

Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. DOS (Dermatan sulphate in Oncologic Surgery) Study Group.

Thrombosis and haemostasis·1999

Dermatan sulphate in patients with heparin-induced thrombocytopenia.

British journal of haematology·1999

Individualized anticoagulation with dermatan sulphate for haemodialysis in chronic renal failure.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·1997

Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia.

Haematologica·2026

Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: "HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial"

Haematologica·2026

Balancing remission durability and treatment burden in older acute myeloid leukemia. Comment on: "Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia".

Haematologica·2026

Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma".

Haematologica·2026

Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.

Haematologica·2026

Defining the therapeutic window of NLRP6 modulation in graft-versus-host disease. Comment on: "NLRP6 regulates donor T cell activation and acute graft-versus-host disease via ZAP-70-Erk pathway".

Haematologica·2026

Targeting host lipogenesis with a diarylamide inhibitor disrupts SARS-CoV-2 replication.

iScience·2026

Modular synthesis of α-tertiary amino acids from C-H feedstocks.

Chemical science·2026

Negative allosteric modulation of NMDA receptors with GluN2B subunit: synthesis of γ-amino alcohols embedded in a 1-benzoxepine scaffold.

RSC medicinal chemistry·2026

Synthesis of photoactive compounds from 2H-pyran-2-ones and their photophysical properties.

RSC advances·2026

DABPU-DE targeting host adipose triglyceride lipase provides broad-spectrum anti-coronavirus effects in vitro.

Frontiers in pharmacology·2026

Inhibition and Molecular Recognition of Lactoperoxidase by Acetohydrazide-Based Sulfonamide Derivatives.

Journal of molecular recognition : JMR·2026

Related Experiment Videos

Dermatan sulfate as a potential antithrombotic drug

Related Concept Videos

Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study.

A placebo-controlled, double-blind study of mesoglycan in the treatment of chronic venous ulcers.

Clinical outcome and its predictors in 1560 patients with critical leg ischaemia. Chronic Critical Leg Ischaemia Group.

Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. DOS (Dermatan sulphate in Oncologic Surgery) Study Group.

Dermatan sulphate in patients with heparin-induced thrombocytopenia.

Individualized anticoagulation with dermatan sulphate for haemodialysis in chronic renal failure.

Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia.

Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: "HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial"

Balancing remission durability and treatment burden in older acute myeloid leukemia. Comment on: "Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia".

Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma".

Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.

Defining the therapeutic window of NLRP6 modulation in graft-versus-host disease. Comment on: "NLRP6 regulates donor T cell activation and acute graft-versus-host disease via ZAP-70-Erk pathway".

Targeting host lipogenesis with a diarylamide inhibitor disrupts SARS-CoV-2 replication.

Modular synthesis of α-tertiary amino acids from C-H feedstocks.

Negative allosteric modulation of NMDA receptors with GluN2B subunit: synthesis of γ-amino alcohols embedded in a 1-benzoxepine scaffold.

Synthesis of photoactive compounds from 2H-pyran-2-ones and their photophysical properties.

DABPU-DE targeting host adipose triglyceride lipase provides broad-spectrum anti-coronavirus effects in vitro.

Inhibition and Molecular Recognition of Lactoperoxidase by Acetohydrazide-Based Sulfonamide Derivatives.

Related Experiment Videos

Dermatan sulfate as a potential antithrombotic drug

Related Concept Videos

Related Articles